US Stock Insider Trading | Oncolytics Biotech disclosed two insider transactions on March 13

K-LinePoet · 2026-03-13T14:06:12+00:00

Oncolytics Biotech recently disclosed insider stock transactions involving multiple directors and executives, including Director Parsons James T. purchasing 10,000 shares on March 11, as well as stock purchases by several other directors in February. The company is focused on developing the immunotherapeutic agent pelareorep to boost the immune system's ability to fight cancer.

K-LinePoet

2026-03-13 14:06:12

Abstract generation in progress

Oncolytics Biotech (ONCY) disclosed two insider transactions on March 13, 2026. Director Parsons James T. purchased 10,000 shares on March 12, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 13, 2026	Director	Kelly Jared	March 12, 2026	Buy	5,050	0.96	4,848.00
March 13, 2026	Director	Parsons James T.	March 11, 2026	Buy	10,000	1.03	10,300.00
February 13, 2026	Director	Pisano Wayne	February 12, 2026	Buy	30,000	0.84	25,300.00
February 13, 2026	Director	Seizinger Bernd R.	February 12, 2026	Buy	40,000	0.85	33,900.00
February 13, 2026	Director	Brown Deborah Margaret	February 12, 2026	Buy	25,000	0.85	21,200.00
February 13, 2026	Director	Andrews Patricia S	February 12, 2026	Buy	35,400	0.86	30,300.00
February 13, 2026	Director	Kelly Jared	February 11, 2026	Buy	5,600	0.84	4,681.60
February 13, 2026	Executive	Aromando Andrew	February 11, 2026	Buy	29,600	0.86	25,400.00
February 13, 2026	Executive	Look Kirk	February 12, 2026	Buy	12,000	0.84	10,100.00
February 13, 2026	Executive	Heineman Thomas Charles	February 12, 2026	Buy	12,100	0.83	10,000.00

【Company Profile】

Oncolytics Biotech Inc. was incorporated on April 2, 1998, under Alberta law as Alberta Limited Liability Company. The company is a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenous immunotherapy that activates both innate and adaptive immune systems and weakens tumor defenses. This enhances the immune system’s ability to fight cancer, making tumors more susceptible to a broad range of tumor therapies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes